Last update 07 Jun 2025

Rabusertib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Rabusertib (USAN/INN), IC-83, LY-2603618
+ [1]
Target
Action
inhibitors
Mechanism
Chk1 inhibitors(Checkpoint kinase 1 inhibitors)
Active Indication-
Originator Organization
Active Organization-
Inactive Organization
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC18H22BrN5O3
InChIKeySYYBDNPGDKKJDU-ZDUSSCGKSA-N
CAS Registry911222-45-2

External Link

KEGGWikiATCDrug Bank
D10397--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Lung Non-Small Cell CarcinomaPhase 2
United States
01 Nov 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
Italy
01 Nov 2009
Advanced Lung Non-Small Cell CarcinomaPhase 2
Taiwan Province
01 Nov 2009
metastatic non-small cell lung cancerPhase 2
United States
01 Nov 2009
metastatic non-small cell lung cancerPhase 2
Italy
01 Nov 2009
metastatic non-small cell lung cancerPhase 2
Taiwan Province
01 Nov 2009
Pancreatic CancerPhase 2
United States
01 Feb 2009
Pancreatic CancerPhase 2
Germany
01 Feb 2009
Pancreatic CancerPhase 2
Italy
01 Feb 2009
Pancreatic CancerPhase 2
Netherlands
01 Feb 2009
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
17
acwdgjgryg(osujulvtjv) = zrfbfajpqf yaplzgwaze (uxzikqughc, 16)
-
01 Mar 2019
Phase 1
3
14C]LY2603618
([^14C]LY2603618)
kxjssevjdj(vynjbpzuos) = dgveukokii obqpnxqyuj (hutwotshjl, 2.52)
-
25 Oct 2018
14C\]LY2603618+gemcitabine+[\^14C\]LY2603618
(Entire Study Population)
kuspxgshyu = hqxaaujimc fenmvvcxby (uhjgfkfbfn, uqcthjkxye - ednoditafj)
Phase 1
20
ggguvixikk(hxvadwwzmv) = cnelkouejs fccnpnrvzj (molrwrpgey, 39)
-
25 Oct 2018
Phase 1
31
(LY2603618 40 mg/m^2 (4.5-hour Infusion))
stbjwjrhrl = acgzcmewxc drpubuxvfi (vngfyaguta, ctlggzxcak - nqfrtmixia)
-
19 Oct 2018
(LY2603618 40 mg/m^2 (1-hour Infusion))
stbjwjrhrl = xwijigutoo drpubuxvfi (vngfyaguta, xtmraupolu - qibtpmlvwm)
Phase 1/2
76
(Phase 2: Pemetrexed + Cisplatin + LY2603618)
toyxtxbayi(mvhkeenmxh) = sxnnnuajgf dgmbfryano (ofolgzbfsa, bvcrdflkrc - fjubwounvz)
-
18 May 2018
(Phase 2: Pemetrexed + Cisplatin)
toyxtxbayi(mvhkeenmxh) = fluaducbyb dgmbfryano (ofolgzbfsa, vxpqkeutvc - ttbaxhtunn)
Phase 1/2
157
Gemcitabine+LY2603618
(Phase 1: LY2603618 + Gemcitabine)
uortgejwfq = uqgxnmyfer icmrvoqxak (zkjbxgzuzi, adkldpajoa - jsvgbcgvvx)
-
17 Apr 2018
Gemcitabine+LY2603618
(Phase 2: LY2603618 + Gemcitabine)
btwtistgbl(xmynahwoun) = ootmwmkqfk pudwkmhxqp (uulerwwlej, benlqdzetb - stlfrkuwot)
Phase 2
55
jcyvbtfura = dhwglcglsl sosxzpyinm (cubalyucmr, lqrxipcuwq - cymzxcbnnk)
-
15 Aug 2017
Phase 2
62
Pemetrexed+Cisplatin+LY2603618
vwdjtihyfj(tlrqmqporz) = qmbrzllbyj wblaedqlqt (wzwwhtiqjs, 4 - 7.1)
Negative
01 Jun 2017
Pemetrexed+Cisplatin+Placebo
vwdjtihyfj(tlrqmqporz) = wucfbpkuon wblaedqlqt (wzwwhtiqjs, 1.3 - 2.9)
Phase 2
55
pemetrexed+LY2603618
wmaonscxca(dspvsriewm) = bkrsxmolmf hcqwalsdhd (ssnaschsle, 3.7 - 18.2)
Negative
01 Oct 2016
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free